Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Papi

Showing results (21-30 of 87) with videos related to

Pageof 9
Sort By:
Recenti Progressi in Medicina|December 16, 2015
[Evolving therapeutic targets in inflammatory Bowel Disease: mucosal healing as an emerging end point]Giovanna Condino, Giovanna Margagnoni, Annalisa Aratari, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Methotrexate-induced pneumonitis in a patient with Crohn's diseaseGiovanna Margagnoni, Valeria Papi, Annalisa Aratari, et al.
Recenti Progressi in Medicina|February 17, 2018
[Towards new therapeutic paradigms beyond symptom control in the management of inflammatory bowel diseases.]Stefano Festa, Giulia Zerboni, Annalisa Aratari, et al.
Journal of Clinical Medicine|November 26, 2022
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD TherapiesDaniela Pugliese, Sara Onali, Giuseppe Privitera, et al.
Journal of Clinical Gastroenterology|February 19, 2003
Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhageClaudio Papi, Loredana Gili, Maurizio Tarquini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 24, 2021
No impact of restructuring IBD-related activity during COVID-19 outbreak on patient outcomes. A single Center experienceFabiola De Biasio, Annalisa Aratari, Stefano Festa, et al.
Expert Review of Gastroenterology & Hepatology|June 3, 2014
Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?Simone Saibeni, Gianmichele Meucci, Claudio Papi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 1, 2020
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable"Daniela Pugliese, Claudio Papi, Giuseppe Privitera, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 30, 2012
Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?Federica Fascì Spurio, Annalisa Aratari, Giovanna Margagnoni, et al.
Expert Opinion on Drug Safety|February 24, 2018
A safety evaluation of budesonide MMX for the treatment of ulcerative colitisCristina Bezzio, Stefano Festa, Giulia Zerboni, et al.
Pageof 9

Showing results (21-30 of 87) with videos related to

Sort By:
Pageof 9
Recenti Progressi in Medicina|December 16, 2015
[Evolving therapeutic targets in inflammatory Bowel Disease: mucosal healing as an emerging end point]Giovanna Condino, Giovanna Margagnoni, Annalisa Aratari, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Methotrexate-induced pneumonitis in a patient with Crohn's diseaseGiovanna Margagnoni, Valeria Papi, Annalisa Aratari, et al.
Recenti Progressi in Medicina|February 17, 2018
[Towards new therapeutic paradigms beyond symptom control in the management of inflammatory bowel diseases.]Stefano Festa, Giulia Zerboni, Annalisa Aratari, et al.
Journal of Clinical Medicine|November 26, 2022
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD TherapiesDaniela Pugliese, Sara Onali, Giuseppe Privitera, et al.
Journal of Clinical Gastroenterology|February 19, 2003
Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhageClaudio Papi, Loredana Gili, Maurizio Tarquini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 24, 2021
No impact of restructuring IBD-related activity during COVID-19 outbreak on patient outcomes. A single Center experienceFabiola De Biasio, Annalisa Aratari, Stefano Festa, et al.
Expert Review of Gastroenterology & Hepatology|June 3, 2014
Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?Simone Saibeni, Gianmichele Meucci, Claudio Papi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 1, 2020
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable"Daniela Pugliese, Claudio Papi, Giuseppe Privitera, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 30, 2012
Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?Federica Fascì Spurio, Annalisa Aratari, Giovanna Margagnoni, et al.
Expert Opinion on Drug Safety|February 24, 2018
A safety evaluation of budesonide MMX for the treatment of ulcerative colitisCristina Bezzio, Stefano Festa, Giulia Zerboni, et al.
Pageof 9